IQVIA (IQV) is a publicly traded Healthcare sector company. As of July 5, 2026, IQV trades at $207.04 with a market cap of $34.55B and a P/E ratio of 25.47. IQV moved +1.89% today. Year to date, IQV is -9.07%; over the trailing twelve months it is +25.75%. Its 52-week range spans $134.65 to $247.05. Analyst consensus is strong buy with an average price target of $213.90. Rallies surfaces IQV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IQVIA Shares Face Headwinds as MS Cuts Target to $200 on AI Insourcing: Morgan Stanley downgraded IQVIA Holdings to Equal-weight and cut its price target from $225 to $200, citing potential AI-driven insourcing of up to 30% of clinical trial costs. The firm also flagged higher interest expenses and upcoming debt maturities as constraints on future share repurchases and valuation.
| Metric | Value |
|---|---|
| Price | $207.04 |
| Market Cap | $34.55B |
| P/E Ratio | 25.47 |
| EPS | $8.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $247.05 |
| 52-Week Low | $134.65 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $16.63B |
| Net Income | $1.39B |
| Gross Margin | 0.00% |
13 analysts cover IQV: 0 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $213.90.